Abstract
Introduction
Despite efforts in the last decade to improve its diagnosis and treatment, sepsis represents a major health problem, with a mortality that still remains high (20 -50%) (1) .
The concept of Early Goal Directed Therapy (EGDT) in sepsis, which indicates treatment initiation within 6 hours of the patient's presentation to the emergency department may contribute to a significant reduction in mortality (2, 3) . Effective sepsis management is, nevertheless, based on early diagnosis and rapid identification of high risk patients and severity.
The concept of organ dysfunction employed in the definition of sepsis refers to a complex alteration of biological processes occurring at cellular and metabolic levels, often without a clear-cut clinical differentiation between sepsis as a general symptom and septic shock as a sepsis subcategory (4) . For this reason the contribution of biomarkers with sufficient sensitivity and specificity to sepsis diagnosis, could become crucial (5) .
The interaction between pathogenassociated molecular patterns (PAMPs) and the innate immune system macrophages by pattern recognition receptors (PRRS) represents one of the cellular mechanisms of sepsis occurrence. The balance between consecutively-released proinflammatory and anti-inflammatory mediators is responsible for its clinical status.
Interleukin-6 (IL-6) is encoded by a gene located to chromosome 7p2 region, is a cytokine with key initial proinflammatory role in the systemic inflammatory response to infectious injuries. Several studies demonstrated that IL-6 circulating levels correlate with sepsis severity and mortality rates (6, 7) .
It has been demonstrated that certain single nucleotide polymorphisms (SNPs) in cytokines genes are associated with the risk of sepsis occurrence and its outcome (8) . Recent studies have reinforced the idea of a possible genetic basis for the selection of patients with favorable potential response to personalized therapies, with a growing interest in identification of a sepsis-associated genetic predisposition (9) .
The most studied polymorphism of IL-6 is represented by the transition of guanine (G) to cytosine (C), namely G/C, at the -174 promoter region. In vivo demonstration of the role of G allele, with consequences in increasing the inflammatory response mediated by elevated cytokines circulating levels, underlined the possible involvement of variations within the regulatory part of the IL-6 gene in sepsis incidence and outcome (10, 11) . Results in the literature are still inconclusive, some authors associating this SNP with an increased sepsis risk (10, 12, 13) , while others invalidating such associations (14, 15) or pointing out to its relevance in combination with other gene polymorphisms (16) .
The role of G/C transition at the -572 promoter region of IL-6 is subject to only a few studies on sepsis risk and outcome. These studies suggest a predisposition to systemic infections in patients with GG genotype for IL-6 -572G/C SNP with chronic renal diseases and trauma in certain populations (17, 18) .
The objectives of this study were to investigate the role of IL-6 gene polymorphisms in sepsis susceptibility, severity and outcome, as well as in evaluating their association with its plasma levels.
Materials

Patients and controls
A prospective cohort study was carried out for 10 months, from September 2015 to July 2016, in the Anesthesiology and Intensive Care Clinic of the Emergency Clinical County Hospital from Tirgu Mures, Romania. The study protocol was approved by the Ethics Committees of the participating Hospital (no. 123/2015) and of the University of Medicine and Pharmacy of Tirgu Mures (no. 22462/2015). A written informed consent was signed by the patients or their firstdegree relatives and the consent was archived.
Patients were enrolled according to the following inclusion criteria: Caucasian origin, age over 18 years, and sepsis (presumed/ confirmed infection accompanied by at least two of the following systemic infection manifestations: fever > 38°C or hypothermia < 36°C, tachycardia > 90/min, tachypnea > 20/ min, leukocytosis > 12,000 mm³, leucopenia < 4,000 mm³ or > 10% immature forms).
Septic shock was considered in patients who also associated hypotension (systolic blood pressure < 90 mm Hg or mean arterial pressure < 70 mm Hg) refractory to adequate volume resuscitation (19) . 96 healthy unrelated individuals (44 males, 52 females) sex and age-group matched, without known infections in the previous 18 months, were included in the control group. Criteria for exclusion from the study were represented by: HIV infection, known malignancies, and autoimmune diseases requiring immunosuppressive drugs. They were applied to both patient cohort and the control group.
Study design
Patients were enrolled in the study group within the first 24 hours of sepsis onset, all cases being admitted to the intensive care unit (ICU) from medical or surgical services. The collected data were recorded in a case report form and comprised: clinical data, including the condition requiring admission (i.e. medical or emergency/elective surgical condition), primary situs of infection; severity score upon enrollment in the study (Acute Physiology and Chronic Health Evaluation -APACHE II, Simplified Acute Physiology Score -SAPS II and Sequential Organ Failure Assessment -SOFA), number of hospitalization days in the ICU, days of vasoactive therapy and mechanical ventilation, date of death in case of fatal outcome; anthropometric, clinical, biological (haematological, biochemical), radiological and microbiological data were also recorded for each patient (outside the scope of the current study).
Methods
Blood samples were obtained by cubital venous puncture from each patient who met the inclusion criteria within the first 24 hours following the sepsis diagnosis, between 8 and 9 AM; one sample was collected in ethylenediaminotetraacetic acid (EDTA) coated tubes and centrifuged (1000 X g, 10 min); the obtained plasma was apportioned into small aliquots and stored at −80°C until it was analyzed. Another blood sample was drawn for deoxyribonucleic acid (DNA) isolation.
Genotyping analysis
Rapid isolation of ultra-pure DNA from fresh whole blood samples collected from patients and controls enrolled in the study was performed using the Quick-gDNA MiniPrep kit. For the genotyping of IL-6 single nucleotide gene polymorphisms (SNPs), we used polymerase chain reaction (PCR) methods, namely the restriction fragment length polymorphism (PCR-RFLP) assay for the investigation of IL-6 -572 G/C (rs1800796) SNP (20) and the amplificationrefractory mutation system PCR (ARMS-PCR) method for IL-6 -174 G/C (rs1800795), as previously described (21) .
IL-6 plasma levels determination
To measure the level of circulating IL-6 cytokine in our samples we used the Human premixed magnetic screening assay (R&D Systems, Minneapolis, USA), and a multiplex technique based on xMAP technology (Luminex, Austin TX USA), which allows the detection multiple cytokines in a small sample volume. Measurements were performed according to the manufacturer's instructions.
Analyte-specific antibodies are pre-coated on internally-dyed magnetic beads. After addition of samples and incubation, the analytes of interest will bound to the specific antibodies on the magnetic particles. In a second step, specific biotinylated detection antibodies are added, forming antigen-antibody sandwich complexes, revealed by PE-streptavidin addition. The magnetic beads coupled with immune complexes will be read on a dual laser flow-based Luminex 200 (Luminex Corporation, Austin, USA) detection analyzer, one laser interrogating the type of magnetic bead, the other quantifying the concentration of each analyte by measuring the PE-streptavidin signal. The IL-6 sensitivity for the multi-analyte kit used was 1.7 pg/mL.
Statistical Analysis
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS, version 20, Chicago, IL, USA) software. Data were considered as nominal or quantitative variables. Nominal variables were characterized using frequencies. Quantitative variables were tested for normality of distribution using the Kolmogorov-Smirnov test and were characterized by median and percentiles (25-75%) or by mean and standard deviation (SD), when appropriate. Quantitative variables were compared using t test, Mann-Whitney test or Kruskal-Wallis test, when appropriate. In order to assess the associations between genotype distribution and other categorical variables, we used contingency tables and the chi-square test. We calculated the OR (odds ratio) to demonstrate the probability or susceptibility to sepsis according to the given polymorphisms. Deviations of allelic frequencies from HardyWeinberg equilibrium were calculated using a Chi-square test. Each polymorphism of interest was analyzed as a possible predictor for sepsis using simple binary logistic regression. We interpreted all tests against a p = 0.05 significance threshold and statistical significance was considered for p-values below the significance threshold.
Results
Characteristics of the patients
A total number of 107 patients with sepsis were enrolled in the study. There was no statistically significant difference between the septic patients and controls regarding age (mean 54.1 ± 15.5 years vs 56.8 ± 15.4 years, p = 0.34) and gender (45.8% vs 53.3% male patients, p = 0.29). Patients in the study group were divided into two subgroups based on the above-mentioned inclusion criteria: 60 patients (56,07%) in the organ dysfunctionfree sepsis subgroup (S), and 47 patients (43.92%) in the septic shock subgroup (SS). For further analysis, patients were subsequently sub-divided into: deceased (n = 76) and survivors (n = 31). The main baseline demographic and clinical characteristics are shown in Table 1 . C allele was considered variant for the investigated SNPs. The G allele was dominant in the control group and it was considered to be the wild-type allele. Accordingly, the genotypes found were: variant heterozygotes (GC) or homozygotes (CC) genotypes and wild-type homozygotes GG. Distribution of genotypes in the control group and in the sepsis group, as well as in both septic subgroups was in HardyWeinberg Equilibrium (HWE) for both studied SNPs. ( Table 2 and Table 3 )
IL-6 circulating levels
Patients with septic shock had significantly higher plasmatic IL-6 levels (median 132.9 pg/ mL, range 22.23 -10240 pg/mL), compared to the organ dysfunction-free subgroup (median 54.9 pg/mL, range 13.2-6566 pg/mL) (OR = 2.57, 95% CI = 1.98-6.74, p = 0.0012).
Distribution of the IL-6 -174 G/C Polymorphism
There were no statistically significant differences between septic patients and the healthy control group (p = 0.56). In the whole septic study group, 87.9% of patients had the variant genotype for IL-6 -174 G/C polymorphism, which was similar to the control group (90.6%) (all data shown in Table 2 ). Although the IL-6 -174 GG genotype was more frequent in the septic group (43%) than in the control group (38.5%), the difference was not significant and none of the variant genotypes or allele was associated with sepsis, compared to the controls (Table 4) . Likewise, no significant association with sepsis risk was found in septic patients with variant heterozygous (GC) or homozygous (CC) genotypes, compared to the GG genotype ( Table 2) . Further analysis revealed no differences among the patient subgroups regarding the IL-6 -174 G/C GC heterozygous genotype distribution (p = 0.54) (all the data shown in Table 2 ). However, a higher, almost double percentage of IL-6 -174 G/C CC homozygotes was present in the organ dysfunction-free sepsis group, which might point to a possible protective role of this genotype in the development of severe sepsis, but the difference had no statistical significance, nor was it significant in the GC+CC genotype group compared to the GG genotype septic patients (Table 3) . Moreover, we found no statistically significant difference in the septic shock development risk for C versus G allele (p = 0.66) ( Table 3) .
Evaluation of a possible association between genotypes and mortality seemed to have a similar trend, CC genotype being more common in survivors compared to the deceased (16.1% vs. 10.5%), although overall differences were beyond statistical significance (p = 0.49) ( Table 3) .
Distribution of the IL-6-572 G/C Polymorphism
Regarding the IL-6 -572 G/C SNP, no association was observed between its genotypes and sepsis predisposition, even if heterozygotes GC and homozygotes CC were more frequent in the septic study group (21.5% and 1.9%) compared to controls (16.7% and 1.0%, respectively); similarly, no statistically significant difference between the study and control groups was observed in case of the C allele (12.6% vs. 9.4%), (Table 2) ; this lack of association was supported by logistic regression analysis of IL-6 gene polymorphisms genotypes and allele Table 4) . Compared to GG, the CC or GC+CC genotypes were associated with a significantly different sepsis risk (septic shock and organ dysfunctionfree sepsis subgroups) ( Table 3) . Genotype and allele frequencies in the two septic subgroups for this SNP are listed in Table  3 . Their comparison reveals that GG had a higher frequency in the septic shock subgroup (89.4%) compared with the organ dysfunction-free sepsis subgroup (66.7%), whereas heterozygous GC genotype occurred more frequently in the ODfree septic subgroup (30.0% vs. 10.6%) (p = 0.01); the variant IL-6 GC+CC genotypes were statistically significant more frequent in the less severe septic group (p=0.006) (Table  3) ; likewise, the C allele of this polymorphism was statistically significant re frequent in this subgroup compared to the normal G allele (OR = 0.25; 95% CI = 0.09-0.69, p = 0.004) ( Table  3 ) and patients carrying it were associated with the OD-free septic group (OR = 0.24; 95% CI = 0.08-0.70, p = 0.008) ( Table 4 ). The findings strongly suggest a protective role of this allele in the development of some severe forms of sepsis. However, they were not supported by genotype and allele distribution according to outcome, since there was no association of the C allele with mortality ( Table 3) .
Interrelation between IL-6 levels -IL-6 SNPs
Since patients with septic shock had significantly higher circulating IL-6 levels compared to organ dysfunction-free sepsis patients, we analyzed the possible role of the studied polymorphisms in their occurrence. No significant association between the genotypes of the studied IL-6 polymorphisms and their plasma levels was found in septic patients. Therefore, patients with homozygous GG genotype of the -174 G/C SNP had elevated IL-6 circulating levels but this difference was not statistically significant compared to the other genotypes, either considered separately or together (Table 5) . Moreover, logistic regression analysis of the variant genotypes of IL-6 -174 G/C or -572 G/C SNPs or the alleles was not associated with significantly modified levels of the circulating cytokine in the septic study group (p > 0.05).
Given the differences in serum cytokine levels in the studied subgroups, we investigated the possible association of elevated levels in septic shock patients with the genotypes of the studied polymorphisms. In both polymorphisms, we found a statistically significant difference between subgroups for the GG genotype circulating levels ( Table 5) .
Discussion
Several genetic studies have evaluated the implications of cytokine gene involvement in the inflammatory response for the particular course of infection, some demonstrating the role of genetic background in sepsis susceptibility and its different outcomes.
Alteration of cytokine expression, as an intrinsic component of the innate immunity involved in infection, governed in part by gene variants and especially SNPs, has been demonstrated to influence sepsis risk and its mortality (22) . IL-6 cytokine, which has an essential role in triggering and modulating sepsis systemic inflammation by its fast dynamics that increases early circulating levels in infectious injury, is a promising biomarker in sepsis; the role of genetic variation within the regulatory part of its gene has been evaluated in numerous studies on adults and children with systemic infections.
Two biallelic SNPs located in the IL-6 gene promoter at positions -174 and -572, namely -174 G/C (rs1800795) and -572 G/C (rs1800796), have been associated with modifications in sepsis risk and mortality, possibly through changes in cytokine production and circulating levels (17, 23) . However, the results of their influence on sepsis predisposition and outcome as well as on plasma IL-6 levels are divergent or even contradictory. Our aim was to evaluate this genetic determinism of the two SNPs in a critically ill septic patient (ICU) cohort.
One of our main findings was that IL-6 -174 G/C and IL-6 -572 G/C were not associated with the risk of sepsis development. We first evaluated the association between variant genotype and allele of rs1800795(IL-6 -174 G/C) and sepsis risk and we could not establish any statistically significant correlation. This conclusion is different from the findings of a recent study, in which the C allele was revealed to increase pneumonia-induced sepsis risk (24) , and also from the results published by many authors who studied this aspect on pediatric cohorts (12, 25, 26) . Most of them indicated that the G allele was predictive for sepsis development: Harding et al. in premature newborns, Ahrens et al. in Gram-positive infections in very low birth weight (VLBW) infants, and recently, in infants with early onset sepsis (EOS) (12, 25, 26) . A pediatric study also showed the G allele to be statistically significant more frequent in infected children compared to controls (10). Contradictory findings were revealed by other researchers, underlining that the C allele of IL-6 -174 G/C polymorphism might increase predisposition to sepsis in children and blood stream infections in infants or even favor fungal infections in certain infant populations (27) . There are only few pediatric studies which do not detect any association between IL-6 -174 G/C (28, 29) and sepsis; Chauhan's (2008) metaanalysis found a modest association of this SNP with neonatal sepsis risk (30) . In adults, most authors invalidated this association in different populations: in severe septic adults, including surgical sepsis (31, 32) , in patients with chronic nephropathy (17) , and in systemic infections of uncertain meningococcal and pneumococcal etiology (13, 33) . A recent meta-analysis conducted by Gao et al. strongly demonstrated the lack of evidence of a significant association between IL-6 -174 G/C and sepsis risk, this being consistent with our results (8) .
On the other hand, we found only three studies on the association between IL-6 -572 G/C polymorphism and sepsis risk, all of them with different findings from ours. One study showed a statistically significant association between the wild-type homozygous genotype and sepsis risk in patients with chronic renal disease, the second revealed only a small difference in genotype frequencies between infected children and controls while the third suggested a lower sepsis risk associated to IL-6 -572 G/C gene polymorphism variant in certain populations (10, 17, 18) .
The second goal of our study was to assess the association between IL-6 studied polymorphisms and sepsis severity. To this end, the septic patients under study were divided into two subgroups depending on severity, i.e. organ dysfunction-free and septic shock subgroup (4).
For further analysis, patients were divided according to outcome (exitus/survival) during hospitalization. No association was found between IL-6 -174 G/C gene polymorphism and sepsis mortality, and no significant differences in the frequencies of alleles or genotypes between the OD-free subgroup and the septic shock group. A possible explanation for the lack of significance in differences among subgroups may be due to the heterogeneity of the studied group explained by the fact that we included all patients with sepsis/septic shock during the study period.
Although with partly contradictory results, some studies revealed a statistically significant role of this SNP in sepsis outcome. Most studies provided evidence of an unfavorable role of the CC genotype of Il-6 -174 G/C on sepsis severity (10) , and on GG genotype association with less severe forms of systemic infections and increased survival rates in sepsis (13, 32, 34) .
Homozygous CC genotype involvement of this SNP in haplotype clades that are strongly associated with multiple organ dysfunction syndrome (MODS) and mortality in severe septic patients has also been demonstrated (35) . However, some reports point to the association of GG genotype with severe forms and higher mortality in systemic meningococcal infection and in certain infant populations (25, 33) .
Our results are consistent with recent findings in patients with chronic renal sepsis, and in a group of non-septic severe renal patients, as well as in newborn studies (17, 27, 35) . Lack of IL-6 -174 G/C polymorphism association with sepsis mortality is supported by the meta-analysis conducted by Gao et al. on seven studies, with only one positive correlation with the recessive model (CC vs GC/GG), prior to Bonferroni correction (8) .
Our main finding in the current study was the association between GC genotype of the IL-6 -572 G/C SNP and septic shock. We also conclude that the C allele of IL-6 -572 G/C SNP had a protective role in the development of severe sepsis, in contrast with the results of a pediatric study, which obtained no association of IL-6 -572G/C with sepsis severity (10) . The contradictory results may be consequences of the small number of subgroups.
Numerous studies demonstrated an increase in IL-6 circulating levels in the severe forms of sepsis and septic shock, and provided evidence of their association with sepsis mortality (37, 38) . In our study, the identification of statistically significant elevated plasma levels of IL-6 in septic shock compared to organ dysfunction-free septic patients was consistent with recent studies supporting its role of potential early prognostic biomarker due to its upregulated levels in sepsis, particularly in septic shock (6) .
Our finding regarding the lack of association between variant genotype or allele of IL-6 -174 G/C gene polymorphism and IL-6 plasma levels on the entire group of septic patients supports the results of studies on burn patients with and without sepsis, and polytraumatised patients (35, 39) . On the other hand, the major role of G allele of IL-6 -174 G/C in promoting the inflammatory response is confirmed in our study by the significant increase of IL-6 circulating levels in patients with septic shock in GG genotype but not in the other two genotypes of IL-6 -174 G/C. This finding is similar to the results of other clinical trials which demonstrate the association of GG genotype with increased circulating levels in sepsis (11, 25) ; a single study indicates that C allele of IL-6 -174 G/C is associated with increased IL-6 levels in infants (23) .
On the other hand, the elevated circulating IL-6 levels we obtained in patients with septic shock and GG genotype of IL-6 -572 G/C SNP were similar to Panayides' results in septic patients with chronic nephropathies who developed MODS (17) , and are somehow consistent with the reduced transcriptional activity by IL-6 -572 G/C polymorphisms showed by Gu et al. in a sepsis population (18) .
Significant association of GG genotype of IL-6 -572 G/C with septic shock risk and high IL-6 circulating levels could be arguments for a poor outcome in sepsis. However, our results point out the absence of an association of this genotype with mortality; a possible explanation for this finding could be the deaths by other causes rather than infectious within the group, which could lead to an interpretation bias. Absence of this SNP association with infection-related mortality is supported by two other studies on sepsis-associated chronic nephropathy and in a pediatric group (10, 17) .
To our knowledge, there are very few studies evaluating the role of IL-6 -572 G/C polymorphism in sepsis risk and severity. The three studies in the literature refer to particular patient populations (trauma, chronic renal) or children (10, 17, 18) . Investigation of a population of severe septic patients that is homogeneous as representativeness for the profile of an ICU septic patient by age, source of infection, and Caucasian race, represents the strength of our study. We also emphasize that it advances the new approaches in sepsis definition and reclassification introduced in 2016 (4). We believe that within the context of the most studied IL-6 -174G/C polymorphism, our findings bring additional solid arguments for its lack of association with sepsis risk, severity and mortality. Another strong point of the present study is represented by the fact that two IL-6 SNPs were considered simultaneously.
However, certain limitations of the present study should be mentioned. First, the relatively small number of septic patients and controls under study interferes with the statistical power of the groups; further studies are needed in order to validate these results, especially on IL-6 -174 G/C and -572 G/C polymorphisms, given the paucity of data from other studies as well as the singularity of our results. Secondly, the group is representative of a reduced area for which the clinic provides services (the central region of the country).
conclusions
Our study concludes that IL-6 -174 G/C gene polymorphism has no significant contribution to sepsis risk evaluation and management, it underlines the role of IL-6 -572 G/C SNP as a possible prognostic marker in sepsis, and it reconfirms the IL-6 role as a biomarker in severe sepsis patients. 
